Aptuit, LLC has acquired Kuecept Ltd., expanding capabilities for specialist drug pre-formulation, formulation prototyping and formulation development services.
 
Kuecept, based in London, offers technical expertise in CRO services supporting preclinical drug development. Kuecept provides pre-formulation testing, preclinical dose-vehicle screening and formulation development, along with a range of enabling drug delivery technologies. Kuecept has experience in respiratory, parenteral and oral formulation development for insoluble compounds. Its formulation rescue consultancy helps companies move APIs through IND/CTA enabling safety assessment.
 
Aptuit chief executive officer, Dr. Jonathan Goldman said, “The acquisition of Kuecept enhances our scientific expertise and capabilities in the pre-formulation development space. The addition allows us to improve the transition of compounds from medicinal chemistry in discovery through to formal regulatory based Drug Product Development.”
 
Dr. Mark Saunders, chief executive officer and founder of Kuecept added, “Since our inception in 2007, we have focused our efforts on the provision of flexible, cost effective and responsive preclinical R&D services. Through this acquisition, our customers can now combine our capabilities with Aptuit’s full suite of integrated drug development solutions to facilitate the transition of new drugs through preclinical evaluation to clinical manufacture.”